STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

MAP Verified Summary — reported by STAT News

Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.

This story was scored across MAP’s five-signal verification framework — Context, Presentation, References, Visibility, and Comparison — as part of Media Alert Press’s independent media credibility index. Read the full original story at STAT News →